The impact of hUC MSC-derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity

• Published in: Science advances 2024-04, Vol.10 (14), p.eadl3406
• Main Authors: Aliakbari, Farhang, Marzookian, Kimia, Parsafar, Soha, Hourfar, Hamdam, Nayeri, Zahra, Fattahi, Arghavan, Raeiji, Mohammad, Boroujeni, Narges Nasrollahi, Otzen, Daniel E, Morshedi, Dina
• Format: Article
• Language: English
• Subjects: alpha-Synuclein - metabolism; Diseases and Disorders; Exosomes - metabolism; Humans; Iridoid Glucosides; Materials Science; Neuroscience; Parkinson Disease - pathology; SciAdv r-articles
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.adl3406

Amyloid aggregation of α-synuclein (αSN) protein amplifies the pathogenesis of neurodegenerative diseases (NDs) such as Parkinson's disease (PD). Consequently, blocking aggregation or redirecting self-assembly to less toxic aggregates could be therapeutic. Here, we improve brain-specific nanocarriers using a hybrid of exosomes (Ex) from human umbilical cord mesenchymal stem cells (hUC MSCs) and nanoliposomes containing baicalein (Ex-NLP-Ba) and oleuropein (Ex-NLP-Ole). The hybrids contained both lipid membranes, Ex proteins, and baicalein or oleuropein. Fluorescence resonance energy transfer analysis confirmed their proper integration. The hybrids reduced the extent of αSN fibrillation and interfered with secondary nucleation and disaggregation. They not only reduced αSN pathogenicity but also enhanced drug internalization into cells, surpassing the efficacy of NLP alone, and also crossed the blood-brain barrier in a cellular model. We conclude that Ex can be successfully extracted and efficiently merged with NLPs while retaining its original properties, demonstrating great potential as a theranostic drug delivery vehicle against NDs like PD.